Latest News

UC researchers to study drug’s effects on COVID-19 patients

September 22, 2020

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19. They will study the effects of razuprotafib, an investigational drug that activates a key pathway for stabilizing blood vessels in the lung and other organs in patients with moderate to severe cases of the respiratory illness caused by the novel coronavirus SARS-CoV-2. The drug may prevent and treat respiratory distress in COVID-19 patients. The Phase 2 clinical trial will assess safety, tolerability and efficacy of razuprotafib.

Load More
Debug Query for this